Events

Barcelona, Spain. ORYZON announced today that it will be presenting at the 3rd edition of Clinical Trials for Alzheimer’s Disease (CTAD) which will take place in Toulouse, France on November 3-5, 2010.

The presentation of the progresses of our drug discovery program in EPIGENETIC targets for Alzheimer’s disease will be done in the Pre- CTAD Congress to be done on Wednesday, November 3rd at 10.40-11.10 by Dr Tamara Maes, Chief Scientific Officer with the title First in class disease modifying drugs for Alzheimer’s disease

CTAD brings together the current leaders involved in clinical trials on Alzheimer’s Disease to discuss new results, new drugs development and future methodological issues (disease modifying outcomes, biomarkers, impact on the Healthcare economy...). This conference brings the latest knowledge on AD clinical trials based on the clinical experiences of international teams and is a perfect occasion to exchange with peers on this topic and take home some hands-on therapeutic and methodological tools to improve and reinforce AD clinical trials.